DWC 20161

Drug Profile

DWC 20161

Alternative Names: DWC20161

Latest Information Update: 28 Feb 2017

Price : $50

At a glance

  • Originator Daewoong Pharmaceutical
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 02 Nov 2016 Daewoong Pharmaceutical completes a phase I trial in Undefined indication (In volunteers) in South Korea (unspecified route) (NCT02947139)
  • 01 Sep 2016 Phase-I clinical trials in Undefined indication (In volunteers) in South Korea (unspecified route) (NCT02947139)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top